Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Smith & Nephew reveals collusion attempt

This article was originally published in The Gray Sheet

Executive Summary

Smith & Nephew discloses July 31 that one of its independent sales representatives sent an email Oct. 28, 2005, to competitors seeking cooperation on pricing for hip and knee implants. The London-based firm, which has since severed its relationship with the rep, denies authorizing or acting upon the email. The price-fixing scheme likely prompted an investigation by the U.S. Department of Justice, which subpoenaed Smith & Nephew, Stryker, Johnson & Johnson/DePuy, Biomet and Zimmer in June for documents related to possible antitrust violations (1"The Gray Sheet" July 3, 2006, p. 8). A separate investigation by the U.S. attorney's office in Newark, N.J., pertaining to the relationship between orthopedics manufacturers and physicians is ongoing (2"The Gray Sheet" April 4, 2005, p. 3)...

You may also be interested in...

DoJ Probes Big Orthopedic Firms’ Pricing, Deflating Investor Confidence

The U.S. Department of Justice served subpoenas to the five largest orthopedic manufacturers to investigate suspected industry violations of antitrust laws in pricing hip and knee implants. The specific nature of the inquiry is unknown

DoJ Probe Into Orthopedic Industry Could Rattle Upward Pricing Trend

Several subpoenas of orthopedic manufacturers by the U.S. attorney's office in Newark, N.J. appear to be aimed at alleviating pricing pressure on hospitals for orthopedic devices

India Rare Disease Policy Proposes Crowdfunding But Patients Feel Let Down

Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts